AgomAb Therapeutics (AGMB) FDA Approvals $11.86 -0.46 (-3.70%) As of 11:36 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AgomAb Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by AgomAb Therapeutics (AGMB). Over the past two years, AgomAb Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Ontunisertib. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Ontunisertib FDA Regulatory Events Ontunisertib is a drug developed by AgomAb Therapeutics for the following indication: Fibrostenosing Crohn’s Disease. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - June 23,2026Provided Update Phase 2bDrug: OntunisertibAnnounced Date: June 23, 2026Indication: Fibrostenosing Crohn’s DiseaseAnnouncementAgomab Therapeutics NV announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).AI SummaryAgomab Therapeutics NV has announced the design of its upcoming Phase 2b NOV-ERA study of ontunisertib, an investigational oral, GI-restricted inhibitor of ALK5 for the potential treatment of fibrostenosing Crohn’s disease (FSCD). The study is planned to test three doses of ontunisertib—400 mg, 200 mg, and 100 mg—against placebo in a 1:1:1:1 randomization, with twice-daily dosing. The trial will include a 6-week screening period, a 52-week treatment period, and a 2-week follow-up. Its main goal is to measure the proportion of patients who achieve endoscopic passability of the ileal index stricture at Week 24, a novel endpoint meant to help show whether the treatment can ease bowel narrowing. Agomab said the study is intended to help identify endpoints for later registrational trials. First patient dosing is expected in the second half of 2026, and the company notes that ontunisertib is still experimental and has not been proven safe or effective.Read Announcement AgomAb Therapeutics FDA Events - Frequently Asked Questions Has AgomAb Therapeutics received FDA approval? As of now, AgomAb Therapeutics (AGMB) has not received any FDA approvals for its therapy in the last two years. What drugs has AgomAb Therapeutics submitted to the FDA? In the past two years, AgomAb Therapeutics (AGMB) has reported FDA regulatory activity for Ontunisertib. What is the most recent FDA event for AgomAb Therapeutics? The most recent FDA-related event for AgomAb Therapeutics occurred on June 23, 2026, involving Ontunisertib. The update was categorized as "Provided Update," with the company reporting: "Agomab Therapeutics NV announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD)." What conditions do AgomAb Therapeutics' current drugs treat? Currently, AgomAb Therapeutics has one therapy (Ontunisertib) targeting the following condition: Fibrostenosing Crohn’s Disease. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Acurx Pharmaceuticals FDA EventsAtea Pharmaceuticals FDA EventsHemab Therapeutics FDA EventsIronwood Pharmaceuticals FDA EventsKura Oncology FDA EventsAvidity Biosciences FDA EventsSpero Therapeutics FDA EventsAgilent Technologies FDA EventsAligos Therapeutics FDA EventsANI Pharmaceuticals FDA EventsArtelo Biosciences FDA EventsBiogen FDA EventsBioMarin Pharmaceutical FDA EventsEnlivex Therapeutics FDA EventsErasca FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Bicara Therapeutics FDA Events Iovance Biotherapeutics FDA Events Mesoblast FDA Events Zymeworks FDA Events AnaptysBio FDA Events Rapport Therapeutics FDA Events Taysha Gene Therapies FDA Events Atai Beckley FDA Events Urogen Pharma FDA Events Ascentage Pharma Group International FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:AGMB last updated on 6/24/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredBNZI Lands a Zacks Upgrade!Banzai International (NASDAQ: BNZI) just received a Zacks Rank 2 (Buy) upgrade, driven by improving earnings e...Huge Alerts | SponsoredAmerican’s Biggest Threat Is HereThis feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...Goldco Direct, LLC | SponsoredThey proved it worked in '76. Then buried it.In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AgomAb Therapeutics NV Please log in to your account or sign up in order to add this asset to your watchlist. Share AgomAb Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - June 23,2026Provided Update Phase 2bDrug: OntunisertibAnnounced Date: June 23, 2026Indication: Fibrostenosing Crohn’s DiseaseAnnouncementAgomab Therapeutics NV announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).AI SummaryAgomab Therapeutics NV has announced the design of its upcoming Phase 2b NOV-ERA study of ontunisertib, an investigational oral, GI-restricted inhibitor of ALK5 for the potential treatment of fibrostenosing Crohn’s disease (FSCD). The study is planned to test three doses of ontunisertib—400 mg, 200 mg, and 100 mg—against placebo in a 1:1:1:1 randomization, with twice-daily dosing. The trial will include a 6-week screening period, a 52-week treatment period, and a 2-week follow-up. Its main goal is to measure the proportion of patients who achieve endoscopic passability of the ileal index stricture at Week 24, a novel endpoint meant to help show whether the treatment can ease bowel narrowing. Agomab said the study is intended to help identify endpoints for later registrational trials. First patient dosing is expected in the second half of 2026, and the company notes that ontunisertib is still experimental and has not been proven safe or effective.Read Announcement
